Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, single-arm, single-institution, open label, two-stage phase II and
dose-ranging study designed to evaluate the efficacy and safety of paclitaxel poliglumex in
combination with pemetrexed in patients with advanced stage IIIB or stage IV NSCLC.